Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
1.600
0.00 (0.00%)
Jul 22, 2025, 8:00 PM EDT

Silence Therapeutics Company Description

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease.

Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs.

The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.

Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics plc
Silence Therapeutics logo
CountryUnited Kingdom
Founded1994
IndustryBiotechnology
SectorHealthcare
Employees116
CEOCraig Tooman

Contact Details

Address:
72 Hammersmith Road
London, W14 8TH
United Kingdom
Phone44 20 3457 6900
Websitesilence-therapeutics.com

Stock Details

Ticker SymbolSLNCF
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberGB00B9GTXM62
SIC Code2836

Key Executives

NamePosition
Craig A. Tooman M.B.A.President, Chief Executive Officer and Executive Director
Rhonda L. HellumsExecutive Vice President, Chief Financial Officer and Secretary
Dr. Steven J. Romano M.D.Executive Vice President and Chief Research and Development Officer
Dr. Marie Wikstrom Lindholm Ph.D.Chief Scientific Officer
Gem Gokmen HopkinsHead of IR and Corporate Communications
Gianine EspositoChief Human Resources Officer
Dr. Barbara A. Ruskin J.D., Ph.D.Senior Vice President and Chief Intellectual Property and Innovation Officer
J.P. GabrielChief Technical Operations Officer
Curtis Rambaran M.D.Chief Medical Officer